India Monoclonal Antibodies Market Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029 Segmented By Type (Murine, Chimeric, Humanized, Human), By Application (Cancer, Cardiac/Cardiovascular, Neurological, Others), By Production (In vitro, In vivo), By Biomanufacturing (Originator, CMO), By End Users (Hospitals, Research Laboratories, Others), by region, and Competition
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationIndia Monoclonal Antibodies Market Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029 Segmented By Type (Murine, Chimeric, Humanized, Human), By Application (Cancer, Cardiac/Cardiovascular, Neurological, Others), By Production (In vitro, In vivo), By Biomanufacturing (Originator, CMO), By End Users (Hospitals, Research Laboratories, Others), by region, and Competition
Market Overview
India Monoclonal Antibodies Market has valued at is anticipated to witness an impressive growth in the forecast period with a CAGR of 10.25 % through 2029. Monoclonal Antibodies (mAbs) are a type of laboratory-produced molecules that can mimic the immune system's ability to fight off harmful pathogens such as bacteria, viruses, and other foreign substances. These molecules are designed to target and bind to specific antigens or proteins in a highly precise and specific manner. Monoclonal antibodies are a crucial class of biopharmaceuticals used for various purposes in medicine, including the diagnosis and treatment of diseases. Monoclonal antibodies are engineered to bind with high specificity to a particular antigen. This means they can be designed to target a specific protein, cell, or molecular structure, making them ideal for precision medicine. They are produced by identical immune cells, known as hybridomas, that are clones of a single parent cell. This ensures uniformity and specificity of the antibodies. Monoclonal antibodies have revolutionized the treatment of a wide range of diseases. They are used in the treatment of cancer, autoimmune disorders, infectious diseases, and inflammatory conditions. Some mAbs are designed to block certain proteins involved in disease processes, while others can stimulate the immune system to target and destroy specific cells.
Ongoing research and development efforts led to the discovery of new therapeutic targets and the development of novel mAbs. Advances in biotechnology and genomics contributed to the expansion of the mAbs pipeline. Government support and incentives for the pharmaceutical and biotechnology sectors, including the promotion of research and development in mAbs, encouraged market growth. The Indian pharmaceutical industry's reputation for producing high-quality yet cost-effective generic medicines made mAbs more accessible to a larger patient population. The growth of biosimilars, including biosimilar mAbs, as more affordable alternatives to originator products, expanded the market's reach. Increasing awareness among patients and healthcare providers about the benefits of mAbs led to higher demand for these therapies.
Key Market Drivers
Biosimilars Development
Biosimilars are highly similar versions of approved reference mAbs. They offer a more cost-effective alternative to the originator products. This increased affordability can expand access to mAb therapies, leading to greater demand. The introduction of biosimilars fosters competition in the mAbs market. This competition can result in competitive pricing, which can, in turn, drive demand as healthcare providers and payers seeks cost-effective options.
The availability of biosimilars often leads to market expansion. Patients who were previously unable to access mAb treatments due to cost constraints can now benefit from these therapies, increasing overall demand. Patients and healthcare providers have more treatment options with the availability of biosimilars. This provides the opportunity to choose the most suitable therapy, which can lead to an uptick in mAb demand. The use of biosimilars can help in reducing healthcare costs for both patients and healthcare systems. When the economic burden is lessened, the demand for mAb therapies is likely to increase. As biosimilars undergo rigorous testing to demonstrate their similarity to reference mAbs, healthcare professionals gain confidence in their safety and efficacy. This trust can drive demand.
Biosimilar development often includes international markets. This expansion can increase the accessibility of mAbs in regions where they were previously less found at. In developing countries where healthcare access is limited, the availability of biosimilars can be a game-changer. It can open new markets and lead to a surge in demand for mAb therapies. Regulatory agencies often encourage the development and approval of biosimilars to promote competition and increase access to treatments. Supportive regulations can further drive the development and adoption of biosimilars, leading to increased mAb demand. The development of biosimilars often involves innovations in biotechnology and manufacturing processes. These innovations can spill over into the development of new mAb products, enhancing the overall demand for mAbs. This factor will help in the development of the India Monoclonal Antibodies Market.
Rising Patient Awareness
Patients who are aware of the potential benefits of mAbs and understand their mechanism of action are more likely to consider these therapies as treatment options. Informed patients can actively participate in discussions with healthcare providers and make decisions that align with their treatment preferences. Patient awareness campaigns and educational initiatives about specific diseases that can be treated with mAbs (such as cancer, autoimmune disorders, and infectious diseases) can help individuals understand the role of mAbs in managing these conditions. As patients become more knowledgeable about their diseases, they may inquire about mAb therapies with their healthcare providers. Patients who are well-informed about their treatment options, including mAbs, are more likely to adhere to their prescribed treatment regimens. Improved treatment adherence can lead to better clinical outcomes and a greater demand for mAbs. Patient advocacy organizations and support groups play a crucial role in raising awareness about specific diseases and found at treatments, including mAbs. These groups can provide information, emotional support, and resources to patients, encouraging them to explore mAb therapies.
Patient advocacy and awareness efforts can contribute to the overall demand for mAbs by creating a patient-driven demand for specific therapies. Healthcare providers may see an uptick in patient requests for mAb treatments. Patients who are aware of mAb clinical trials for their specific conditions may choose to participate. Clinical trial participation is vital for advancing mAb research and development, and it can also expose patients to mAb treatments. For conditions associated with stigma or misunderstanding, such as certain mental health disorders, patient awareness campaigns can help reduce stigma, making it more socially acceptable for patients to seek treatment with mAbs.
When patients are aware of mAb therapies that can potentially improve their quality of life and reduce the burden of disease, they are more likely to request these treatments from their healthcare providers. Informed and aware patients are more likely to engage in shared decision-making with healthcare providers. This collaborative approach can lead to the selection of treatment options that align with patients' values and preferences, potentially including mAbs. Increased patient awareness can drive the growth of the mAbs market by creating demand for these therapies and encouraging pharmaceutical companies to invest in research and development. This factor will pace up the demand of the India Monoclonal Antibodies Market.
Increasing Access to Affordable Medicines
When mAbs are made found at at an affordable price, a larger portion of the population can access these therapies. This leads to an increase in the number of patients who can benefit from mAbs, driving demand. High healthcare costs can be a barrier to accessing advanced therapies like mAbs. Affordable mAbs make it economically feasible for patients to pursue these treatments, which in turn boosts demand. When the cost of mAbs is more affordable, patients are more likely to adhere to their prescribed treatment regimens. Improved adherence can lead to better clinical outcomes and a sustained demand for these therapies.
Affordable access to mAbs can alleviate the economic burden on patients and their families. It can help reduce out-of-pocket expenses, which is particularly important in chronic diseases that require long-term treatment with mAbs. Lower prices can prompt healthcare providers to consider mAbs for a wider range of patients and indications, potentially leading to an increase in demand for these therapies. Efforts to make mAbs more affordable often involve the development of biosimilars or competitive pricing strategies. Competition in the market can drive down prices, making mAbs more accessible and in higher demand. Government policies and initiatives aimed at making healthcare, including mAbs, more affordable can play a significant role in increasing patient access and, consequently, demand.
Affordable mAbs can encourage health insurance providers to include these therapies in their coverage plans, making them accessible to insured individuals and driving demand. Affordable pricing can also promote the export of mAbs to international markets, further increasing demand. A population with greater access to affordable healthcare, including mAbs, can lead to improved overall health and productivity, contributing to economic development. As economies grow, the demand for healthcare services, including mAbs, can increase. This factor will accelerate the demand of the India Monoclonal Antibodies Market.
Key Market Challenges
Quality Assurance and Manufacturing
The production of mAbs involves complex biotechnological processes, including cell culture, purification, and formulation. Ensuring consistency and quality throughout these processes is challenging. Setting up and maintaining facilities for mAb manufacturing requires substantial investments in infrastructure, equipment, and skilled personnel. Ensuring compliance with Good Manufacturing Practices (GMP) standards is essential. The mAb manufacturing process is subject to strict regulatory oversight to guarantee product safety and efficacy. Compliance with evolving regulatory requirements can be demanding and resource intensive. Managing the supply chain for critical raw materials and reagents needed for mAb production is a challenge, particularly during disruptions such as the COVID-19 pandemic. Skilled professionals in bioprocessing, quality control, and regulatory affairs are needed for successful mAb manufacturing. A shortage of trained personnel can be a challenge. Maintaining sterility and preventing contamination in bioreactors and downstream processing is critical. Even minor contamination incidents can result in production losses and quality issues. Transitioning from laboratory-scale production to commercial-scale manufacturing presents challenges in terms of process scalability, efficiency, and consistency.
Cost and Affordability
The development and manufacturing of mAbs involve complex and resource-intensive processes, contributing to high production costs. This cost burden can be passed on to patients, making mAb therapies expensive. Patients, healthcare providers, and healthcare systems in India are often price sensitive. The high cost of mAbs may limit their adoption, especially in a healthcare market where affordability is a critical factor. Health insurance coverage for mAbs may be limited, which means that many patients must pay for these treatments out of pocket. Affordability can be a major concern in such cases.
Even if patients have health insurance, copayments, deductibles, and other out-of-pocket expenses for mAbs can be substantial. High costs can discourage patients from pursuing these therapies. The high cost of mAbs can create disparities in healthcare access, making it difficult for marginalized or poor populations to benefit from these therapies. High costs can limit market penetration, which affects the adoption of mAbs. A smaller patient pool can impact the commercial success of these therapies. The affordability of mAbs can impact patient compliance. Patients who cannot afford these treatments may not adhere to their prescribed regimens, leading to suboptimal outcomes. In rural areas with limited healthcare infrastructure, affordability issues may exacerbate disparities in access to mAb therapies.
Key Market Trends
Growing Demand for Biologics
India is experiencing an increasing burden of chronic diseases, including cancer, autoimmune disorders, and infectious diseases. Biologics, such as mAbs, have become essential for managing and treating these conditions. Biologics, including mAbs, are designed to target specific proteins, cells, or pathways involved in diseases. This targeted approach often results in more effective and safer treatments compared to traditional therapies. Biologics, especially mAbs, have demonstrated significant clinical efficacy in treating various diseases. Positive outcomes and patient success stories contribute to increased demand. There is a growing emphasis on personalized medicine, which tailors treatments to an individual's genetic and molecular profile. Biologics like mAbs are well-suited for this approach. Patients and healthcare providers in India are becoming more aware of the benefits of biologics, including mAbs. This awareness drives demand as patients request these therapies. As the biologics market grows, so does the development of biosimilars, which are highly similar versions of reference biologics. Biosimilars provide more affordable alternatives, expanding access and demand. Increased competition among pharmaceutical companies has led to more innovative biologics and pricing strategies. Competitive dynamics can further stimulate demand. Indian pharmaceutical companies are expanding their presence in the global biologics market, exporting these therapies to international markets.
Segmental Insights
Type Insights
In 2023, the India Monoclonal Antibodies Market largest share was held by Murine type segment and is predicted to continue expanding over the coming years.
Application Insights
In 2023, the India Monoclonal Antibodies Market largest share was held by Cancer segment and is predicted to continue expanding over the coming years.
End-User Insights
In 2023, the India Monoclonal Antibodies Market largest share was held by
Regional Insights
The North India region dominates the India Monoclonal Antibodies Market in 2023.
Recent Developments
- In October 2020, IAVI, anonprofit research organization dedicated to tackling pressing global healthissues, and Serum Institute of India Pvt. Ltd., a prominent manufacturer ofvaccines and biologics, have jointly announced a collaboration with Merck KGaA,Darmstadt, Germany, a leading science and technology company. This partnershipaims to develop monoclonal antibodies (mAbs) capable of neutralizingSARS-CoV-2, which is co-invented by IAVI and Scripps Research. These mAbs areconsidered innovative solutions for addressing the ongoing COVID-19 pandemic.The agreement capitalizes on the extensive expertise of IAVI and ScrippsResearch in antibody discovery and optimization, particularly from their yearsof work in HIV broadly neutralizing antibody research and development.Furthermore, it leverages the considerable capabilities of Merck KGaA,Darmstadt, Germany, and Serum Institute in designing and scaling up acceleratedmanufacturing processes for mAb production. The global development plan is acollaborative effort led by all three organizations.
- In June 2021, Casirivimaband Indevimab are monoclonal antibodies designed to target the spike protein ofSARS-CoV-2, the virus responsible for COVID-19. These antibodies have been madeavailable in India and are specifically engineered to block the virus fromattaching to and entering human cells. This advanced treatment offersprotection to individuals who have tested positive for COVID-19 and areexperiencing mild to moderate symptoms, with the goal of preventing theircondition from worsening or necessitating hospitalization. This single-doseinfusion-based therapy can be administered either intravenously orsubcutaneously in a hospital's outpatient setting. After receiving the antibodyinfusion, patients are closely monitored for potential side effects for a fewhours. Following this observation period, patients are allowed to return homefor quarantine and are advised to diligently adhere to COVID-19 isolationprotocols.
Key Market Players
- Dr. Reddy's LaboratoriesLtd.
- Bristol Myers Squibb IndiaPvt. Ltd.
- Roche India Pvt. Ltd.
- Intas PharmaceuticalsLimited
- Merck India
- Eli Lilly, and Company(India) Private Limited
- Biocon Limited
- AstraZeneca India Pvt. Ltd.
- Pfizer Limited
| By Type | By Application | By Biomanufacturing | By Production | By End-User | By Region |
|
|
|
|
|
|
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy